UBS lowered the firm’s price target on Alvotech (ALVO) to $6 from $10 and keeps a Buy rating on the shares. The firm is confident in the remediation plan outlined by Alvotech’s management and expects these approvals to occur by year-end 2026, the analyst tells investors in a research note. The firm believes the stock has largely reset after this sequence of negative developments, with expectations now meaningfully lower.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech price target lowered to $4 from $5 at Barclays
- Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands
- Is ALVO a Buy, Before Earnings?
- Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group
- Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80